Back to top
more

Biolase (BIOL)

(Real Time Quote from BATS)

$0.15 USD

0.15
272,215

+0.01 (4.17%)

Updated Apr 25, 2024 12:13 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities

by Zacks Equity Research

Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.

Here's Why You Should Add STERIS (STE) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.

Hill-Rom (HRC) New LT Strategy Aids, Y/Y Comparisons Ail

by Zacks Equity Research

Hill-Rom's (HRC) newly initiated long-term growth strategies through fiscal 2022, focusing on all four strategic priorities, look attractive at this moment.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on strong demand for NexSys PCS system and potential of Hemostasis Management franchise.

Henry Schein (HSIC) Dental Sales Grow Globally Despite Pandemic

by Zacks Equity Research

Widespread network and channel mix along with favorable long-term trends in the dental business bode well for Henry Schein (HSIC).

Haemonetics (HAE) Rides on Plasma Arm Recovery Amid COVID Woes

by Zacks Equity Research

Haemonetics' (HAE) hospital business is recovering primarily driven by continued improvement in hospital procedures.

QIAGEN (QGEN) to Boost NeuMoDx Production With US DOD Contract

by Zacks Equity Research

QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.

Here's Why You Should Add Neogen (NEOG) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) on strength in its Food Safety and Animal Safety business segments.

Thermo Fisher (TMO) Expands Biologics Network With New Facility

by Zacks Equity Research

Thermo Fisher's (TMO) Lengnau site will offer biopharma companies a pathway from development to large-scale production.

NEOGEN (NEOG) Inks Genomic Selection Deal With Hendrix

by Zacks Equity Research

Hendrix Genetics with the help of NEOGEN's (NEOG) Genomics will be able to genotype the elite animals in the population.

Here's Why You Should Invest in Quest Diagnostics (DGX) Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.

Medtronic (MDT) Hugo RAS System Used for 1st Clinical Procedure

by Zacks Equity Research

Medtronic's (MDT) Hugo RAS system is a modular, multi-quadrant platform intended for a broad range of soft-tissue procedures.

IDEXX (IDXX) CAG Placement Grows Globally Amid Cost Woes

by Zacks Equity Research

IDEXX's (IDXX) global reference lab revenues are growing organically, reflecting growth in the United States and the international markets.

Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.

NuVasive (NUVA) Expands Training Opportunities With New Center

by Zacks Equity Research

NuVasive's (NUVA) East Coast Experience Center reflects the company's commitment to provide best quality surgeon education and training to enhance the standard of patient care in spine surgery.

Here's Why You Should Add Omnicell (OMCL) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Omnicell (OMCL) on its strategic acquisitions and partnerships supporting each of the three legs of its strategy.

Here's Why You Should Invest in Align Technology (ALGN) Now

by Zacks Equity Research

Investors continue to be optimistic about Align Technology (ALGN) on robust second-quarter 2021 performance and raised guidance.

Abbott's (ABT) Portico With FlexNav System Gets FDA Approval

by Zacks Equity Research

Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Henry Schein (HSIC) Betters Strategic View With Restructure Plan

by Zacks Equity Research

Henry Schein's (HSIC) new organizational structure will continue to enhance the company's exposure to faster-growing and higher-margin markets.

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and solid global performance.

Sanghamitra Saha headshot

Rising P/E: An Ignored Trick to Land on 5 Winning Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Can BIOLASE (BIOL) Stock Continue to Grow Earnings?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider BIOLASE (BIOL).

New Strong Sell Stocks for April 14th

by Zacks Equity Research

BABA, BIOL, CTK, GOL, and JKS have been added to the Zacks Rank #5 (Strong Sell) List on April 14, 2021

Here's Why You Should Hold on to Stryker (SYK) Stock Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.